Arlocabtagene autoleucel
- Generic Name
- Arlocabtagene autoleucel
J&J's Carvykti Shows Promise in Earlier Myeloma Treatment
• The CARTITUDE-4 study indicates that Carvykti (ciltacabtagene autoleucel) significantly improves progression-free survival in multiple myeloma patients with 1-3 prior lines of therapy.
• Carvykti, a BCMA-directed CAR-T therapy, may soon be used earlier in the treatment pathway, potentially leapfrogging Bristol-Myers Squibb's Abecma.
• The study compared Carvykti to standard three-drug regimens, showing a significant benefit that led to unblinding of the trial.
• Expansion of Carvykti's use is a key component of J&J's strategy in multiple myeloma, alongside other therapies like Darzalex and bispecific antibodies.
Arlo-Cel and Antio-Cel Show Promise in Relapsed/Refractory Multiple Myeloma
• Arlocabtagene autoleucel (arlo-cel) demonstrated a 91% overall response rate in heavily pretreated multiple myeloma patients, regardless of high-risk cytogenetics or prior BCMA-directed therapy.
• Antio-cel showed a 95% overall response rate and a 62% complete/stringent complete response rate in relapsed/refractory multiple myeloma, with 92% of patients achieving minimal residual disease negativity.
• Both arlo-cel and antio-cel exhibit manageable safety profiles, with common adverse events being hematological and cytokine release syndrome, respectively, and no unexpected neurotoxicities observed with antio-cel.
BMS-986393 CAR-T Shows Promise in Relapsed/Refractory Multiple Myeloma
• BMS-986393, a GPRC5D-targeted CAR T-cell therapy, demonstrated a 96% objective response rate in patients with relapsed/refractory multiple myeloma after 1-3 prior lines of therapy.
• The phase 1 trial showed a stringent complete response rate of 37.5% and a very good partial response rate of 33.3% at a median follow-up of 5.3 months.
• The CAR-T therapy exhibited a manageable safety profile, with cytokine release syndrome being mostly low grade and neurotoxicity occurring in a small percentage of patients.
• Ongoing studies are evaluating BMS-986393 as a monotherapy and in combination with other agents for relapsed/refractory multiple myeloma, addressing an unmet need.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath